Gilead, Teva Document Disclosures Helped Sway Jury In Rare Pay-For-Delay Trial

Teva’s counsel notes a key factor in the jury's finding that Gilead’s patent settlement with Teva did not include a reverse payment to delay entry of Truvada and Atripla generics. A second trial will proceed on claims a collaboration agreement between Gilead and Janssen was anticompetitive.